LLY

714.52

-4.44%↓

JNJ

146.39

-1.44%↓

UNH

308.04

-0.79%↓

ABBV

177.11

-5.79%↓

NVO

64.32

-1.7%↓

LLY

714.52

-4.44%↓

JNJ

146.39

-1.44%↓

UNH

308.04

-0.79%↓

ABBV

177.11

-5.79%↓

NVO

64.32

-1.7%↓

LLY

714.52

-4.44%↓

JNJ

146.39

-1.44%↓

UNH

308.04

-0.79%↓

ABBV

177.11

-5.79%↓

NVO

64.32

-1.7%↓

LLY

714.52

-4.44%↓

JNJ

146.39

-1.44%↓

UNH

308.04

-0.79%↓

ABBV

177.11

-5.79%↓

NVO

64.32

-1.7%↓

LLY

714.52

-4.44%↓

JNJ

146.39

-1.44%↓

UNH

308.04

-0.79%↓

ABBV

177.11

-5.79%↓

NVO

64.32

-1.7%↓

Search

Cerus Corp

Cerrado

SectorSanidad

1.25 -4.58

Resumen

Variación precio

24h

Actual

Mínimo

1.24

Máximo

1.31

Métricas clave

By Trading Economics

Ingresos

-5.2M

-7.7M

Ventas

-7.6M

43M

BPA

-0.04

Margen de beneficios

-17.85

Empleados

614

EBITDA

-5.8M

-5.9M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+256.49% upside

Dividendos

By Dow Jones

Próximas Ganancias

31 jul 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-1.9M

258M

Apertura anterior

5.83

Cierre anterior

1.25

Noticias sobre sentimiento de mercado

By Acuity

61%

39%

332 / 382 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Weak Bullish Evidence

Cerus Corp Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

14 may 2025, 23:40 UTC

Acciones populares

Stocks to Watch: UnitedHealth Group, Foot Locker, CoreWeave

14 may 2025, 23:33 UTC

Principales Movimientos del Mercado

UnitedHealth Group Shares Fall After WSJ Reports of Investigation for Possible Medicare Fraud

14 may 2025, 23:25 UTC

Principales Movimientos del Mercado

Biohaven Shares Down as FDA Extends PDUFA Data for Troriluzole

14 may 2025, 23:25 UTC

Ganancias

Xero Lifts Fiscal Year Profit 30% on Higher Prices, Subscriber Growth -- Update

14 may 2025, 22:58 UTC

Ganancias

Xero Lifts Fiscal Year Profit 30% on Higher Prices, Subscriber Growth

14 may 2025, 21:35 UTC

Ganancias

Cisco Systems Names Patterson as CFO, Patel as President

14 may 2025, 23:59 UTC

Charlas de Mercado

Implications of Xero's Cost Outlook Aren't Clear -- Market Talk

14 may 2025, 23:49 UTC

Charlas de Mercado

Xero's Cost Outlook Likely to Prompt Downgrades -- Market Talk

14 may 2025, 23:48 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

14 may 2025, 23:48 UTC

Charlas de Mercado

Nikkei May Decline on Profit-Taking After Recent Gains -- Market Talk

14 may 2025, 23:47 UTC

Charlas de Mercado

Gold Gains on Possible Technical Recovery -- Market Talk

14 may 2025, 23:34 UTC

Adquisiciones, fusiones, absorciones

Agnico-Eagle Mines to Subscribe for 30M Voting Common Shares of Foran Mining in Non-Brokered Private Placement at C$3 a Share

14 may 2025, 23:10 UTC

Ganancias

Xero Lifts FY Profit 30% on Higher Prices, Subscriber Growth -- Update

14 may 2025, 23:07 UTC

Ganancias

CoreWeave Posts Strong Revenue and Wins Google as a Customer. Stock Still Dives on Outlook. -- Barrons.com

14 may 2025, 23:00 UTC

Principales Noticias

UnitedHealth Group Is Under Criminal Investigation for Possible Medicare Fraud -- WSJ

14 may 2025, 22:43 UTC

Ganancias

Xero Lifts FY Profit 30% on Higher Prices, Subscriber Growth

14 may 2025, 22:34 UTC

Ganancias

Xero Expects 1H Operating Expense Ratio to Be Higher Than 2H>XRO.AU

14 may 2025, 22:33 UTC

Ganancias

Xero Expects FY26 Operating Expense Ratio of 71.5%>XRO.AU

14 may 2025, 22:30 UTC

Ganancias

Xero Did Not Declare a Dividend>XRO.AU

14 may 2025, 22:30 UTC

Ganancias

Xero FY Operating Expenses 71.8% of Operating Revenue Vs. 73.3%>XRO.AU

14 may 2025, 22:30 UTC

Ganancias

Xero FY Free Cashflow Margin 24.1% Vs. 20.0%>XRO.AU

14 may 2025, 22:30 UTC

Ganancias

Xero FY Free Cashflow NZD506.7M Vs. NZD342.1M>XRO.AU

14 may 2025, 22:28 UTC

Ganancias

Xero FY Ebitda NZD638.5M Vs. NZD497.4M>XRO.AU

14 may 2025, 22:28 UTC

Ganancias

Xero FY Adjusted Ebitda NZD640.6M Vs. NZD526.5M>XRO.AU

14 may 2025, 22:27 UTC

Ganancias

Xero FY Rev NZD2.10B Vs. NZD1.71B >XRO.AU

14 may 2025, 22:27 UTC

Ganancias

Xero FY Net NZD227.8M Vs. Net NZD174.6M >XRO.AU

14 may 2025, 22:23 UTC

Principales Noticias

Boeing, GE Aerospace Get Qatar Airways Order After Saudi AI Tech Deals -- 2nd Update

14 may 2025, 22:15 UTC

Ganancias

Correction to Cisco Earnings Article -- WSJ

14 may 2025, 21:48 UTC

Ganancias

CoreWeave Posts Strong Revenue but Stock Dives on Updated Outlook -- Barrons.com

14 may 2025, 21:37 UTC

Ganancias

Cisco Reports Solid Earnings. The Stock Is Rising. -- Barrons.com

Comparación entre iguales

Cambio de precio

Cerus Corp previsión

Precio Objetivo

By TipRanks

256.49% repunte

Estimación a 12 Meses

Media 4.67 USD  256.49%

Máximo 5 USD

Mínimo 4 USD

De acuerdo con 4 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Cerus Corp Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

4 ratings

3

Comprar

1

Mantener

0

Vender

Puntuación técnica

By Trading Central

1.3 / 1.36Soporte y Resistencia

Corto Plazo

Weak Bullish Evidence

Medio plazo

Strong Bearish Evidence

Largo Plazo

Bearish Evidence

Sentimiento

By Acuity

332 / 382 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura bajista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Cerus Corp

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation was incorporated in 1991 and is headquartered in Concord, California.